
A pediatric dermatologist explains how to read itch, sleep, and quality-of-life findings from phase 2 nemolizumab data in children aged 2 - 11.
Lawrence Eichenfield, MD, of Rady Children's Hospital-San Diego, who discusses the importance of multidisciplinary in the dermatology specialty.


